Industry Explorers Blaze On
-
To America, A New Biopharma Model
9/1/2023
Ketan Mehta, founder and CEO of Tris Pharma. Mehta came to the U.S. in the late 1970s. Since then, he has built a career in pharma and, more recently, an entirely new company with a triad of businesses — platform technology licensing, generic medicines, and new drug development.
-
Nurses: One Of Life Sciences’ Most Valuable Assets
9/1/2023
With many years of experience working in pharma/biopharma, Janice Nissen is convinced that more companies should be building and supporting a greater network of medical professionals within their organizations — with a specific focus on nurses.
-
Biotech Veteran Pushes New Science And Regulatory Change
9/1/2023
Ashvattha Therapeutics CEO Jeff Cleland hopes to bring hydroxyl dendrimer therapeutics to market for the first time, while also pushing for policy and regulatory change as an advocate for BIO.
-
Benefits Of Clinical Development Outsourcing Models
9/1/2023
ISR’s Clinical Development Outsourcing Models (5th Edition) report examines three outsourcing models commonly used in the clinical trial space. Respondents provided feedback on the benefits of each outsourcing strategy currently used at their company.
-
Companies To Watch: Nido Biosciences
9/1/2023
See why Nido Biosciences is developing small molecule drugs for rare neurodegenerative diseases.
-
How To Make The RTO More Productive For Employees
9/1/2023
As workers return to the office, the workplace will need to be tailored to better support their needs. Some of the considerations — from flexible hybrid options to new kinds of office environments — may inspire more employees to come back in person.
-
3 Traits For Compliance Execs To Become Business Leaders
9/1/2023
Evaluating a wider range of inputs and forming your own strategic viewpoint aligned with business priorities enables you to pivot to being a business leader, rather than an advisor to business leaders.
-
Corporate Social Responsibility: Action Builds Community
9/1/2023
Despite the hand-wringing that often accompanies conversations around corporate social responsibility (CSR), there is nothing controversial about basic human needs.
-
Companies To Watch: Ventoux Biosciences
8/1/2023
Why Ventoux Biosciences is pursuing drug treatments for all sufferers of Dupuytren’s and other fibroproliferative diseases.
-
The Immigrant Approach To Biotech Formation
8/1/2023
Flagship Pioneering General Partner Avak Kahvejian, Ph.D., says successfully ideating new biotech companies — which Flagship has done in spades — requires the curiosity, skepticism, and paranoia of a new inhabitant in foreign land. Oh, and a little bit of machine learning won’t hurt.